Chime Biologics and Great Bay Bio enter into Strategic Alliance
[July 6, 2021 GMT +8] – Great Bay Bio Holdings Limited (hereinafter referred to as “GBB”), a high-tech enterprise dedicated to applying cutting-edge artificial intelligence technology to biologic drug development, announced today that it has reached a strategic partnership with Chime Biologics, a world-class CDMO company based in Wuhan, China, to jointly promote Klone4.0TM technology. Together, we aim to empower the pharmaceutical industry by means of AI technology.
Klone4.0TM is an AI-enabled cell line development platform, which is independently developed by GBB. Proven through robust experimental results, the platform can precisely select high yielding cell lines quickly and with high certainty. In addition, Klone4.0TM can screen hundreds of thousands of cells at one time. The proprietary AI algorithm quickly analyze the massive data of cell images obtained by a specialized microscope, obtaining high-yielding and high-quality cell lines within 4 hours, thus greatly accelerating the cell line development process. The use of image recognition and AI disrupts traditional trial-and-error methodology of drug development, greatly avoiding enormous repetitive work. While saving human and financial resources, it can greatly improve the probability of successful screening, making cell line development simpler and more efficient.
Dr. Liang Chen, Co-founder and CEO of GBB, said, “We are pleased to form a strategic alliance with Chime Biologics. With its world-class GMP quality and manufacturing system, extensive international CDMO service experience and outstanding execution ability, Chime perfectly complements our innovation prowess, enabling a fast access to a solid customer base, accelerating commercialization of Klone4.0TM to further optimize our platforms. This partnership will serve as a new milestone of GBB’s development and drive the company to grow faster in an effort to make GBB’s long-standing vision ‘making global biologic development faster and more efficient’ a reality and deliver benefits to people around the world.”
Dr. John Zeng, CEO of Chime Biologics, said, “We are excited to partner with GBB and to offer accelerated cell line development services to our clients. GBB’s Klone4.0TM platform will enable faster, more accurate and high quality clone selection together with our cell line platform. Then application of Klone4.0 with our process development and GMP manufacturing expertise will allow our clients to enter clinical studies earlier. Sharing with common vision, we believe that we will accelerate biopharmaceutical commercialization process and benefit patients worldwide”
About Great Bay Bio
Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to biopharmaceutical development and other blue ocean bio-products, ultimately solving numerous pain points of biopharmaceutical industry, including high failure rates, long development timeline and high costs. Since the company’s establishment, it has obtained massive data from conventional biologics development. GBB has also successfully brought a number of biologic products to NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created the intelligent centralized database, where deep learning is being performed to create next generation of AI-enabled bioprocessing ecosystem.
About Chime Biologics
Chime Biologics, a China-based, world-class Contract Development and Manufacturing Organization (CDMO), provides customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. It provides one stop comprehensive solution supporting our customers from early-stage biopharmaceutical development through late-stage clinical and commercial manufacturing, catering to the evolving needs of the dynamic biopharmaceutical industry. It pledges to make world-class biopharmaceuticals affordable and accessible to all patients globally through technological and manufacturing innovation, and empowering therapeutic advancement for the improvement of human health.
Chime Biologics is ISO 14001:2015 and ISO 45001:2018 certified. With the State-of-the-art facility and in-house world class expert teams, it is committed for excellence upholding highest degree of integrity. Its World’s first GE KuBio facility is located at Wuhan’s BioLake biotech industry development zone of China, with clear path to expand the total capacity up to 140,000+ in the near future.
